Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

From cutting-edge treatment methods to the integration of new technologies, the International Conference on Advances in Radiation Oncology (ICARO-4) promises to inspire and equip conference attendees ...

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Co-authored by investigators of VHIO's Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results of a ...

Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial ...

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...

Co-authored by investigators of VHIO’s Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results of a study recently published open access as an Original ...

The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

Merus expects the FDA to make a decision on the application in February after reviewing additional manufacturing information it submitted.

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.